Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Needed to plus 1 this! Great news!!
Wild action already today! Heavy volume!
Foamix Pharmaceuticals First Quarter 2019 Financial Results Conference Call & Webcast Scheduled for May 8
Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will report its financial results for the first quarter ended March 31, 2019, on Tuesday, May 7, after the markets close. Foamix will host a conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, May 8.
Conference Call & Webcast Wednesday, May 8th @ 8:30am Eastern Time Toll Free: 877-407-0784 International: 201-689-8560 Conference ID: 13689852 Webcast: http://public.viavid.com/index.php?id=134118 A replay of the call will be archived on the Company's website at www.foamix.com promptly after the confer ence call.
Upper Street is also pleased to announce that it is completing its fully audited financial statements, and expects to file for both full SEC compliance and to uplist to the OTCQB markets over the next weeks.
Upper Street Marketing Inc. Announces Strategic Partnership in Canada
San Diego, CA, April 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Upper Street Marketing Inc. (OTC Market, trading symbol UPPR) and its wholly-owned subsidiary, Growing Springs Holding Corporation, has announced a strategic partnership with Catch Capital Partners Inc. (CATCH) to jointly develop cannabis and hemp production and extraction in Canada. Under the terms of the partnership arrangement, UPPR will acquire a twenty percent (20%) interest in the common voting equity of CATCH in exchange five million common voting shares of UPPR.
“UPPR is excited to join forces with the experienced management team at CATCH to develop their immediate and future [outdoor] cultivation and extraction projects which have the potential to provide significant cannabis and hemp supply,” said Joseph Earl, the Chief Executive Officer of UPPR. Mr. Jeff Wareham, the Chief Executive Officer of CATCH, added that “Our strategic partnership with UPPR provides strong complementary synergies and is expected to accelerate the development of our near-term and longer-term initiatives. We are particularly excited that UPPR has a formal working relationship with PrimaPharm, a San Diego based cGMP certified pharmaceutical producer, which will enable CATCH to ensure their products and processes meet what we believe will be the gold standard for the burgeoning medical cannabinoid market.” Upper Street Marketing Inc. is a publicly traded Oklahoma Corporation that specializes in acquisition, finance and management of hemp cultivation, extraction and CBD manufacturing in Colorado and other US States. UPPR is uniquely serving its target markets with cGMP grade cultivation and manufacturing standards. The rapidly expanding hemp, CBD and cannabis markets in the North American and world markets is a perfect opportunity for UPPR and Growing Springs Holdings Corporation. UPPR and Growing Springs Holdings Corporation are ideally positioned to capitalize on recent regulatory changes that dramatically enhance opportunities in hemp production and CBD extraction as well as FDA concerns regarding use of CBDs in the marketplace. Growing Springs Holdings Corporation website is www.growingspringsholdings.com. CATCH is an Ontario, Canada based company focused on outdoor cannabis and hemp production. Catch has identified a unique property with the potential to be a market leading outdoor project. The project offers exceptional access to infrastructure, existing facilities uniquely suited to cannabis production, access to freshwater; gas, municipal water, and over 200 acres of highly productive agricultural land. Catch is actively seeking to develop further properties suitable for hemp and cannabis production.
Upper Street is also pleased to announce that it is completing its fully audited financial statements, and expects to file for both full SEC compliance and to uplist to the OTCQB markets over the next weeks. Cautionary Language Concerning Forward-Looking Statements Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend”, and similar expressions, as they relate to the Company or its management, identify forward-looking statements. These statements are based on current expectations, estimates, and projections about the Company’s business, based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors. Such statements could be affected by risks and uncertainties related to: (i) our ability to execute the Company’s business plans with the uncertainty of agricultural crops (ii) product demand, market, and customer acceptance of the Company’s products, (iii) the Company’s ability to obtain financing to expand our operations, (iv) the Company’s ability to attract qualified sales representatives, (v) competition, pricing and development difficulties, (vi) the Company’s ability to conduct the business if there are changes in laws, regulations, or government policies related to the Company’s products, (vii) the Company’s ability to conduct operations if it faces product recalls, and (viii) general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release.
https://www.apnews.com/Globe%20Newswire/879ae33af0b13f9a2825a00ae0317825
Ya know! Once past this dreadful RS we have warrants expiring and excitement building towards rosacea P2 results!
Still hanging around, huh Dr? Let us know if you find the right answer!
Nice! Company right on track with moving up!
Yeah, been burned on SL settings myself before. As far as concern for more dilution, I truly believe we're good till after P2 results. We just received $3.9M from the private tutes deal that gives us enough money to make it to the finish line.
Honestly, any peep of news with all the eyes, Vol, day trader's, well, we fly! Only excitement towards P2 from here on out!
IMO the price should stabilized back to the value where we were at today (.0833) in the coming days.
Where things could get crazy is if news comes. If we get another offering after R/S, then the price drops to that offering, but if Tierney has been working on a collaboration, partnership, or something with HYANTX then we won't be looking at a loss.
Remember, a private offering to tutes just took place. Something positive must have been spoken about to have them fund when they knew how close we were to the SEC price above .20 deadline. Why didn't they just wait?
Tierney has a stellar background in correcting company failures and I believe he's doing exactly what needs to be done. Possibly part of investors agreed upon plan. I still stand Long and Strong behind this investment!
This ol dog had way too many fleas! We were never going to climb up out of the hole! Fresh start indeed!
Nobody wanted a R/S but that's where Anja took us! We needed to get out of this hole and time ran out. Tierney did what he had to do. Now let's see if Mr. Merger and Acquisitions has been working on a bigger plan for our future! He wasn't brought on to fail and taint his track record!!
Yeah, Friday the 26th we wake up with our shares divided by 25. But like I said, the outstanding shares will be around 10.5M! Lower float!!
Tomorrow? You mean 2 Fridays from today. (April 26 / Friday)
After split, stock will be around $2.00 with a 10.5M float. News on P2 due in July!
BioPharmX Announces Reverse Stock Split
SAN JOSE, Calif., April 15, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that its Board of Directors has approved a reverse stock split of its common stock at a ratio of 1-for-25. The reverse stock split will become effective on April 25, 2019 (the "Effective Date"), and the shares will begin trading on the split-adjusted basis on the NYSE American under the Company's existing trading symbol "BPMX" at market open on April 26, 2019. The new CUSIP number following the reverse stock split will be 09072X 309.
As a result of the reverse stock split, every 25 shares of the Company's issued and outstanding common stock will automatically combine into one issued and outstanding share of common stock. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's percentage ownership interest in the Company. Proportionate voting rights and other rights of common stock holders will not be affected by the reverse stock split. The reverse stock split will also apply to common stock issuable upon the exercise of the Company's outstanding stock options and warrants. The number of authorized shares of common stock and par value of common stock will remain unchanged.
The reverse stock split is primarily being effected to regain compliance with certain NYSE American continued listing standards related to the low price per share of the Company's common stock. It was initially approved by the Company's stockholders at the Company's annual stockholder meeting held on August 14, 2018 at a ratio of between 1-for-2 and 1-for-25. On April 15, 2019, the Company's Board of Directors approved the reverse stock split at the ratio of 1-for-25 and the effective date of April 25, 2019.
No fractional shares will be issued as a result of the reverse stock split; stockholders who would otherwise hold a fractional share of the Company's common stock will receive cash in an amount equal to the product obtained by multiplying (i) the closing sale price of the common stock on the Effective Date of the reverse stock split as reported on NYSE American, by (ii) the number of shares of the common stock held by the stockholder that would otherwise have been exchanged for the fractional share interest.
The Company's transfer agent, Computershare, will act as the exchange agent for the reverse stock split and will provide instructions to stockholders of record regarding the process for exchanging shares. Stockholders who hold their shares in brokerage accounts or "street name" are not required to take action to effect the exchange of their shares and their positions will be automatically adjusted pursuant to the broker's particular process.
Additional information about the reverse stock split and stockholder approval can be found in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission (the "SEC") on July 6, 2018, and in the Company's Current Report on Form 8-K filed with the SEC on August 17, 2018, each of which is available on the SEC's website, www.sec.gov, and the Company's website, www.BioPharmX.com.
"With more than 25 deals “in the pipeline,” Mintz said there are enough to choose from to keep Innovest growing."
Damon Mintz, Innovest president
Getting in now will have you set up pretty nicely IMO!
https://www.wallstreetpr.com/why-a-potential-ivst-breakout-deserves-a-close-look-41318
Foamix Announces Settlement of Litigation with Perrigo Relating to Finacea Foam
Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) ("Foamix" or the "Company"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that, together with LEO Pharma, it has settled the Hatch-Waxman litigation with Perrigo, relating to Finacea(R) Foam. Terms of the settlement are not disclosed.
"Together with LEO Pharma, we are pleased to have settled the outstanding litigation with Perrigo," said David Domzalski, Chief Executive Officer of Foamix. "We will continue to vigorously defend our existing patents and explore opportunities to further expand our intellectual property portfolio around our proprietary foam products and technologies."
Foamix is the owner of patents that have been licensed to LEO Pharma to market Finacea(R) Foam, a topical prescription medicine used to treat the inflammatory papules and pustules of mild to moderate rosacea. Foamix's lead development candidates, FMX101 and FMX103, are based on a different foam technology platform and different patents than those listed in the Orange Book for the foam technology used in Finacea.
As required by law, the parties will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review.
Patent infringement litigations related to Finacea Foam continue against Teva Pharmaceuticals USA, Inc. and Taro Pharmaceuticals U.S.A. and Taro Pharmaceutical Industries, Ltd.
In it to win it!
Great to know! Appreciate that info!
I don't. Why, what are you thinking?
Don't see any news now that can push us into compliance. It will be interesting to see how Tierney handles this one.
Definitely less friction in decision making! Tierney still cleaning house!!
Bye bye Anja...
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 24, 2019, Anja Krammer, a member of the Board of Directors (the “Board”) of BioPharmX Corporation (the “Company”), informed the Board of her decision to resign from the Board, effective March 24, 2019. Ms. Krammer’s resignation was not in connection with any known disagreement with the Company on any matter.
Volume above average today!
Yeah, I was in that one. Jumped out way too early before the huge run. Still kicking myself, lol.
Keep watch on UPPR! News building for a run. Still a sleeper!
Nice! Make your money, but think about leaving some as an investment.
Didn't fall below .09 so that's a positive!
Good thing there are other stocks out there for you then. I'm good with my investment!
Q BioMed's Diagnostic Kit Designed to Serve Unmet Need for 70 Million Glaucoma Sufferers
Making moves!!
That would be ideal and what we want to see!
Tierney hinted at the conference about finishing rosacea (BPX-04) first. They may just shift focus there for now.
Exactly! I actually just cancelled my .1176 order, lol. I'll buy lower now!!
As long as we keep away from .06 we will recover.
BioPharmX Announces $3.9 Million Offering
BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 43,645,000 shares of common stock at a price of $0.09 per share in a registered direct offering. The gross proceeds of the offering are expected to be approximately $3.9 million.
https://mma.prnewswire.com/media/510652/BioPharmX_Corporation_Logo.jpg
Net proceeds of the offering will be used to advance the BioPha rmX clinical programs, product development and general corporate purposes.
The offering is expected to close on March 25, 2019, subject to customary closing conditions.
Roth Capital Partners acted as sole placement agent.
The shares of common stock were offered by BioPharmX pursuant to a shelf registration statement on Form S-3 (File No. 333-229459) which was declared effective by the Securities and Exchange Commission ( SEC) on February 13, 2019. A prospectus supplement relating to the offering will be filed with the SEC.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. When available, copies of the prospectus supplement and accompanying base prospectus relating to this offering may be obtained from Roth Capital Partners, 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660, (800) 678-9147 or by accessing the SEC's website, www.sec.gov.
Demand Explodes and Supply takes Upper Street (OTC:UPPR)
https://www.wallstreetpr.com/demand-explodes-and-supply-takes-upper-street-otcuppr-41331